Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 16/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461301 | 0.83 | NLRP3 (0.40) | NLRP3CA2GSTO1 | |
| SCHEMBL25506637 | 0.83 | NLRP3 (0.40) | NLRP3CA2GSTO1 | |
| SCHEMBL23674522 | 0.80 | NLRP3 (0.39) | NLRP3ATMSMN1; SMN2CA2ALDH1A1 | |
| SCHEMBL20681034 | 0.75 | NLRP3 (0.41) | NLRP3ATMSMN1; SMN2CA2ALDH1A1 | |
| SCHEMBL20713466 | 0.75 | NLRP3 (0.54) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25197678 | 0.74 | — | — | |
| SCHEMBL25211193 | 0.74 | BCHE (0.36) | — | |
| SCHEMBL20681634 | 0.72 | NLRP3 (0.51) | NLRP3ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL25210032 | 0.70 | — | — | |
| SCHEMBL21646768 | 0.66 | NLRP3 (0.43) | NLRP3ATMSMN1; SMN2GSTO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885ATM 1651/4885SMN1; SMN2 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.